Fingolimod (FTY720), a sphingosine-1-phosphate receptor (S1PR) modulator, was the first oral therapy approved by US Food and Drug Administration (FDA) and European Medicines Agency (EMA) for the treatment of relapsing-remitting multiple sclerosis[1]. To date, fingolimod has not been studied in epilepsy models; however, a recent study performed in the lithium-pilocarpine rat model of SE (status ...

Exposure to organophosphate (OP) nerve agents, such as sarin, may lead to uncontrolled seizures and irreversible brain injury and neuropathology. In rat studies, a median lethal dose of sarin leads to approximately half of the animals developing seizures. Whereas previous studies analyzed transcriptomic effects associated with seizing sarin-exposed rats, our study focused on the cohort of sarin...

Kindling is a very suitable animal model for studying basis mechanisms of epilepsy. In this model , repeated exposure to weak electrical or chemical increases neuronal excitability and there fore decreases the threshold for induction of epileptic seizures. According to abundant distribution of opioid peptides and their receptors in different brain structures and also the role of these receptors...

Background: Epilepsy is a chronic disease characterized by the occurrence of recurrent non provoked epileptic seizures. This condition affects quality life those affected as well their caregivers’ not only itself but also because comorbidity. It requires daily care and continuous use anti seizure medication at specific times day.

Ketogenic diets are high in fat and low in carbohydrates and represent a well-established and effective treatment alternative to anti-epileptic drugs. Ketogenic diets are used for the management of a variety of difficult-to-treat or intractable seizure disorders, especially pediatric refractory epilepsy. However, it has been shown that this dietary therapy can reduce seizures in people of all a...

how to cite this article: mollamohammadi m, tonekaboni sh, pirzadeh z, vahedian m . pregabalin in childhood epilepsy: a clinical trialiran j child neurol. 2014 autumn;8(4): 62-65. abstract objective the prevalence of active epilepsy is about 0.5–1%, and approximately 70% of patients are cured with first anti-epileptic drugs and the remaining patients need multiple drugs. pregabalin as an add-on...

Introduction Eslicarbazepine Acetate, a novel anti-epileptic drug has been approved as monotherapy in focal onset seizures, with/without secondary generalization adults. many advantages over older drugs and is useful patients of new epilepsy. Objectives Aim our study was to determine the efficacy safety observe its well-tolerated use monitor adverse effects newly diagnosed Methods Study done at...

BACKGROUND Non-ketotic hyperglycemia (NKHG) may increase the probability of seizures and movement disorders. METHODS We describe a series of 14 elders admitted for seizures and movement disorders linked to NKHG. RESULTS Twelve patients developed motor seizures and two others movement disorders. Glucose levels varied 9.28 to 32 mmol/l, while osmolarity values varied from 302.28 to 328 mosmol...

This article has been withdrawn at the request of the author(s) and/or editor. The Publisher apologizes for any inconvenience this may cause. The full Elsevier Policy on Article Withdrawal can be found at http://www.elsevier.com/locate/withdrawalpolicy.

Several signaling pathways are believed to be involved in the epileptogenic process that triggers the subsequent changes in the brain causing epilepsy. The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that in the brain, regulates several important physiological functions such as neuronal development and synaptic plasticity, and also seems to be involved in many pathologies,...